Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.

MLA

Anderson, Amy E., et al. “Immunity 12 Years after Alemtuzumab in RA: CD5⁺ B-Cell Depletion, Thymus-Dependent T-Cell Reconstitution and Normal Vaccine Responses.” Rheumatology (Oxford, England), vol. 51, no. 8, Aug. 2012, pp. 1397–406. EBSCOhost, https://doi.org/10.1093/rheumatology/kes038.

APA

Anderson, A. E., Lorenzi, A. R., Pratt, A., Wooldridge, T., Diboll, J., Hilkens, C. M. U., & Isaacs, J. D. (2012). Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. Rheumatology (Oxford, England), 51(8), 1397–1406. https://doi.org/10.1093/rheumatology/kes038

Chicago

Anderson, Amy E, Alice R Lorenzi, Arthur Pratt, Tom Wooldridge, Julie Diboll, Catharien M U Hilkens, and John D Isaacs. 2012. “Immunity 12 Years after Alemtuzumab in RA: CD5⁺ B-Cell Depletion, Thymus-Dependent T-Cell Reconstitution and Normal Vaccine Responses.” Rheumatology (Oxford, England) 51 (8): 1397–1406. doi:10.1093/rheumatology/kes038.